Dimerix

Dimerix Operating Expenses

The Total Operating Expenses of Dimerix (DXB.AX) as of Oct 11, 2026 is 41.06 M AUD. In the previous year, Total Operating Expenses was 32.21 M AUD — a change of 27.47% (higher).

Operating Expenses

41.06 MAUD

YoY

27.47%

Last updated:

Total Operating Expenses of Dimerix is 2026 41.06 M AUD. Total Operating Expenses of Dimerix was 2025 32.21 M AUD. It decreases by 27.47% higher compared to the previous year.

The Dimerix Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
4.05 M AUD
Jan 1, 2020
6.84 M AUD
Jan 1, 2021
10.89 M AUD
Jan 1, 2022
16.83 M AUD
Jan 1, 2023
22.75 M AUD
Jan 1, 2024
24.22 M AUD
Jan 1, 2025
32.21 M AUD
Jan 1, 2026
41.06 M AUD
The Dimerix Operating Expenses history
YEAROperating ExpensesYoY
41.06 MAUD+27.47%
32.21 MAUD+32.99%
24.22 MAUD+6.45%
22.75 MAUD+35.24%
16.83 MAUD+54.53%
10.89 MAUD+59.23%
6.84 MAUD+68.99%
4.05 MAUD+17.31%
3.45 MAUD+52.60%
2.26 MAUD+27.15%
1.78 MAUD+159.06%
686,189.00AUD+48.48%
462,145.00AUD—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Total Operating Expenses of Dimerix is 41.06 M AUD in 2026.

Total Operating Expenses of Dimerix changed from 32.21 M AUD to 41.06 M AUD, representing a 27.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Dimerix since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Dimerix historically and in real time.

Access this data via the Eulerpool API

Income Statement — Dimerix

All Key Metrics — Dimerix